Compare Radana Bhaskara Finance Tbk. (HDFA) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Radana Bhaskara Finance Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Radana Bhaskara Finance Tbk. trades at Rp100 (market cap 660.79B, 428K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Radana Bhaskara Finance Tbk. is far larger — about 6.3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| HDFA | SCPI | |
|---|---|---|
Market Cap | 660.79B | 104.4B |
Volume | 428K | — |
Lot | 4.28K | — |
Turnover | 42.84M | — |
Average Price | 100.09 | — |
Value | 42.84M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Radana Bhaskara Finance Tbk.
PT HD Finance (the company) was incorporated under the name of PT Indonesia Lease Corporation base on notarial deed No.41 of Mr FA Tumbuan, S.H, dated 20 Sep, 1972. The Company's name has been changed from PT HD Finance Tbk to PT Radana Bhaskara Finance Tbk based on the Notarial Deed No. 136 dated May 21, 2014 of Jimmy Tanal, S.H., M.Kn.
Read more on HDFA →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
